High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer. - Test2 - elhamkhani - TriplyDB

High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.

High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.

http://www.wikidata.org/entity/Q34128962

about

New perspectives on targeted therapy in ovarian cancer Crizotinib synergizes with cisplatin in preclinical models of ovarian cancer.Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian Cancer Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome.Betacellulin induces Slug-mediated down-regulation of E-cadherin and cell migration in ovarian cancer cells.Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells.Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells.EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway.Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner.A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models.Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer.Tumor evolution and chemoresistance in ovarian cancer Ovarian Tumor Microenvironment Signaling: Convergence on the Rac1 GTPase

P2860

Q28082524-09D2ADF8-8730-4C80-A859-C32C44D313AE Q33623108-A6856A4E-53FD-462C-BB18-D9932FE813E6 Q33829859-70A6AA19-A76C-4DB9-8033-6C15FB00760C Q35882323-52DC655E-D90D-45A7-8224-2C6163221A45 Q35888647-442A591C-CB41-48A7-9F09-53A6381109D2 Q36139294-BC67FC70-775D-4B5F-BCC3-D7BCE21B6B7C Q37301693-C994DCE7-5BA3-41C8-8CCC-FA856EC3B755 Q37337898-968C990D-46F2-46E7-BA53-D59962783E38 Q37739569-C35786BB-486F-4AE6-B437-EF6403E2461D Q38288773-62B556ED-50F3-4D23-98F0-8E2E09661DE8 Q38652339-92B591BD-BD59-4BB1-8247-C02950F4B75D Q38826628-C3AC22E3-4352-48D6-B11A-7DF903369D56 Q40443875-A713CF97-621C-4C78-82B4-0584B2D13840 Q49339070-E127DC8F-2FC0-40CF-B09A-E5CCA1AD88E2 Q51110603-41483DB8-0ECA-4A54-AC87-241479BA5BFC Q54979642-6148FAFE-8F98-459D-8655-7574A57F6EBC Q58733743-2A7E7397-B1D7-4AB3-951D-B1676F49CFFA Q59126829-05E7CA54-D412-434F-A488-A790DA8FD2E9

P2860

High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.

http://www.wikidata.org/entity/Q34128962

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.

@ast

High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.

@en

High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.

@nl

type

label

High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.

@ast

High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.

@en

High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.

@nl

altLabel

High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer

@en

prefLabel

High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.

@ast

High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.

@en

High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.

@nl

P1433

Q34128962-5019E1AB-2DAB-47C2-B542-54617EE0FD83

P1476

Q34128962-6ABC39D4-08DA-493B-A6BE-2F6D00F5F4BF

P2093

Q34128962-00B34D6B-0278-4B90-8CED-02A6145AB889

Q34128962-30CBCB15-14AF-4C95-9E5C-7542695B58AD

Q34128962-674AAC72-E180-4489-BBF2-1CE7D44F69E3

Q34128962-74CD6B72-0E2E-4EBA-8468-6D162665B46B

Q34128962-B6F16FA0-3131-4016-948B-C89A78533A7D

Q34128962-C65506F2-66C1-4E00-852A-342CBF83B40C

P2860

Q34128962-0C28B1F6-2D01-4513-8FDA-82FBF416C1DE

Q34128962-1748C2B0-0C04-4798-A06A-A1E2BBE21260

Q34128962-1DABF8BD-207F-410F-A789-411E1480ADA9

Q34128962-20B59739-9868-4364-9A86-3BF02718268E

Q34128962-20E1044A-0135-4F2B-AB8C-66352E044B06

Q34128962-26E35DD5-F713-49E8-97F2-8FFC9F75B57F

Q34128962-287B2694-6F53-4C8F-BD21-6E1CEC585FBB

Q34128962-2B1A3DF5-7223-4219-B87C-FEEBE0F584D8

Q34128962-2E13E3FD-CEE8-4BBE-9B0A-568BB435D56A

Q34128962-30AB82FB-9246-4DD4-B851-C3227E4D0D93

P304

Q34128962-23AA8430-C5B4-4BF6-9D40-828D2CA63CF2

P31

Q34128962-B770AF73-975E-4DF6-AE05-41AF3399DB0A

P356

Q34128962-7BD8F157-479E-4D26-A274-5F4528A58E1D

P407

Q34128962-7DBE84AA-9B21-4DF6-B83D-58F54CB901BA

P433

Q34128962-CB9C113D-9EC5-410D-86CB-4D00FEF6E45C

P478

Q34128962-BC48C0FF-87F0-4372-AFDD-5175D3C4C7D7

P50

Q34128962-DB9F1A41-1308-4FA7-98A7-B1FC17E5B0D9

P577

Q34128962-80BB828B-5CDA-4A59-8B61-2C5DBD10B543

P698

Q34128962-FFAC530F-5911-4E8D-8C59-920C19288CCA

P921

Q34128962-3C818C64-76FC-4DB4-BFE4-235AEFF3CA84

P932

Q34128962-F42198F7-6E46-496F-81C2-16E104449E17

P356

PGP.0000000000000081

P1433

International Journal of Gynecological Pathology

P1476

High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.

@en

P2093

Anna Holmes

http://www.w3.org/2001/XMLSchema#string

Bridget S Wilson

http://www.w3.org/2001/XMLSchema#string

Huining Kang

http://www.w3.org/2001/XMLSchema#string

Lesley Lomo

http://www.w3.org/2001/XMLSchema#string

Mara P Steinkamp

http://www.w3.org/2001/XMLSchema#string

Suzy Davies

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Cancer statistics, 2012

Untangling the ErbB signalling network

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer.

Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study.

Targeted therapies in epithelial ovarian cancer.

P304

402-410

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/PGP.0000000000000081

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Carolyn Y. Muller

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24901400

http://www.w3.org/2001/XMLSchema#string

P921

P932

4153698

http://www.w3.org/2001/XMLSchema#string